The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
Clinical trial NCT02063607 · COMPLETED
Trial details
- NCT number
- NCT02063607
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2015-02-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.